Janssen announces US FDA approval of Spravato® (esketamine) CIII nasal spray to treat depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.

The Federal Court of Appeals in Canada ratified a Ministry of Health decision to refuse to provide Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson JNJ, data protection for Spravato ...

Wednesday, J&J’s Janssen unit rolled out data from the phase 3b ESCAPE-TRD trial pitting its esketamine spray Spravato against extended-release quetiapine, formerly marketed by AstraZeneca as ...

Spravato should be used in conjunction with an oral antidepressant, according to both the FDA and Janssen. The FDA said this is the first time esketamine was approved for any use. The agency ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Period to remission was shortened with esketamine nasal spray in both sub-groups within study Period to remission was shortened with esketamine nasal spray in both sub-groups within study The Janssen ...

Xian Janssen Pharmaceutical Ltd. obtained marketing approval in China for Spravato (esketamine hydrochloride nasal spray) in combination with an oral antidepressant to treat depressive symptoms in ...

SPRAVATO ® builds on Janssen's more than 50-plus-year history and commitment to research that makes a difference for people living with mental illnesses, including severe mood disorders.

In 2019, the FDA granted approval to Janssen Pharmaceuticals' Spravato (esketamine) nasal spray in conjunction with an oral antidepressant for patients with TRD. The new medication is a ...